Global Antimalarial Drugs Market 2024–2033

Reports Description

As per the current market research conducted by CMI Market Research Team, the global Antimalarial Drugs market is expected to record a CAGR of 4.6% from 2023 to 2030. In 2023, the market size is projected to reach a valuation of USD 877.59 million. By 2030, the valuation is anticipated to reach US$ 1202.21 million.

The Antimalarial Drugs Market refers to the global market for pharmaceutical products that are used for the prevention and treatment of malaria, a life-threatening disease caused by the Plasmodium parasite. antimalarial drugs can be administered as a prophylactic to prevent the occurrence of malaria or as a treatment for individuals already infected with the disease.

The market includes various drug types, such as artemisinin-based combination therapies, quinoline-based drugs, and others, and it serves both the public health sector as well as the private sector. The market is driven by the rising prevalence of malaria in developing countries, increased awareness of the disease, and government initiatives to control and eliminate malaria.

Antimalarial Drugs Market – Significant Growth Factors

The Antimalarial Drugs Market is expected to witness significant growth in the coming years, driven by several factors, including:

1. Rising Prevalence of Malaria: The increasing prevalence of malaria in developing countries, particularly in Sub-Saharan Africa, is a major driver of the market. The disease affects millions of people every year, and there is a significant need for effective treatments.
2. Government Initiatives: Several governments around the world have launched initiatives to control and eliminate malaria. These initiatives include funding for research and development of new drugs, as well as programs to distribute existing drugs in high-risk areas.
3. Increased Awareness: Public awareness of malaria and its impact on public health has increased in recent years, leading to increased demand for antimalarial drugs.
4. Research and Development: There has been a surge in research and development efforts to develop new and more effective antimalarial drugs. This has resulted in the introduction of several new drugs in the market.
5. Technological Advancements: Advancements in technology have led to the development of more advanced diagnostic tools and treatments, which have increased the effectiveness of antimalarial drugs and led to their increased adoption.

Overall, the Antimalarial Drugs Market is expected to grow significantly in the coming years, driven by these and other factors.

Attributes	Value
Antimalarial Drugs Market Expected Value (2023)	USD 877.59 million
Antimalarial Drugs Market Forecast Value (2030)	USD 1202.21 million
Antimalarial Drugs Market Expected CAGR (2023 to 2030)	4.6%

Antimalarial Drugs Market – Mergers and Acquisitions

The Antimalarial Drugs Market has witnessed several mergers and acquisitions in recent years. Some of the notable ones include:

1. Novartis Acquisition of Coartem: In 2001, Novartis acquired the rights to Coartem, a combination therapy of artemether and lumefantrine, from the Chinese pharmaceutical company Guangzhou Pharmaceuticals Corporation. Coartem has become a leading drug in the antimalarial drugs market.
2. Sanofi Acquisition of Synthelabo: In 1999, Sanofi acquired Synthelabo, a French pharmaceutical company, which had a strong presence in the antimalarial drugs market. This acquisition helped Sanofi expand its product portfolio in the field.
3. Pfizer Acquisition of Ferrosan: In 2011, Pfizer acquired the Danish pharmaceutical company Ferrosan, which had a strong presence in the antimalarial drugs market. The acquisition helped Pfizer expand its presence in the market.
4. Cipla Acquisition of Medpro: In 2013, Indian pharmaceutical company Cipla acquired South African pharmaceutical company Medpro, which had a significant presence in the Antimalarial drugs market in Africa. This acquisition helped Cipla expand its business in the region.
5. GlaxoSmithKline Acquisition of Okairos: In 2013, GlaxoSmithKline acquired Okairos, a Swiss biotechnology company, which had a strong focus on developing vaccines for infectious diseases, including malaria.

Overall, these mergers and acquisitions have helped companies strengthen their position in the antimalarial drugs market, expand their product portfolios, and increase their reach in different regions.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Antimalarial Drugs Market	Orthodontics Market	Cardiac Catheters
CAGR 4.6% (Approx)	CAGR 10.7% (Approx)	7.65% (Approx)
US$ 1202.21 million by 2030	US$ 7,637.8 million by 2030	USD 25.5 billion by 2030.

Antimalarial Drugs Market – Significant Threats

The Antimalarial Drugs Market faces several significant threats that could impact its growth in the coming years, including:

• Drug Resistance: The development of drug-resistant strains of the Plasmodium parasite is a significant threat to the effectiveness of antimalarial drugs. This could lead to the development of new strains of malaria that are resistant to existing drugs.
• Lack of Access: Despite the availability of effective antimalarial drugs, access to these drugs is limited in many regions, particularly in rural areas of developing countries. This limits the market potential for these drugs.
• High Cost: The cost of antimalarial drugs is often high, particularly for newer drugs. This limits access to these drugs for many people in developing countries.
• Competition from Other Treatments: Other treatments for malaria, such as insecticide-treated bed nets and indoor residual spraying, are also effective in preventing the spread of the disease. These treatments compete with Antimalarial drugs in the market.
• Regulatory Challenges: The regulatory environment for antimalarial drugs can be challenging, particularly in developing countries. This can create barriers to entry for new drugs and limit the market potential for existing drugs.

Overall, these threats could impact the growth of the Antimalarial Drugs Market in the coming years. However, continued investment in research and development, as well as efforts to improve access to drugs and reduce costs, could help to mitigate these threats and drive growth in the market.
Report Scope

Feature of the Report	Details
Market Size in 2023	USD 877.59 Million
Projected Market Size in 2030	USD 1202.21 Million
Market Size in 2022	USD 831.21 Million
CAGR Growth Rate	4.6% CAGR (2022-2030)
Base Year	2023
Forecast Period	2024-2033
Key Segment	By Drug Class, Distribution Channel, and Region
Report Coverage	Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope	North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options	Request tailored purchasing options to fulfil your requirements for research.

Category-Wise Insights

By Drug Class:

• Quinine: Quinine is a natural alkaloid that has been used for centuries to treat malaria. It is effective against all species of Plasmodium, but is often used in combination with other drugs due to its potential side effects.
• Chloroquine: Chloroquine is a synthetic drug that has been widely used to treat malaria since the 1940s. However, the development of resistance to the drug has limited its effectiveness in many regions.
• Proguanil: Proguanil is a synthetic drug that is often used in combination with other drugs, such as chloroquine or atovaquone, to treat malaria. It is effective against both P. falciparum and P. vivax.
• Mefloquine: Mefloquine is a synthetic drug that is effective against both drug-resistant and drug-sensitive strains of the Plasmodium parasite. It is often used in combination with other drugs.
• Pyrimethamine: Pyrimethamine is a synthetic drug that is often used in combination with sulfadoxine to treat malaria. The combination is known as Fansidar and is effective against P. falciparum.
• Others: Other drugs used to treat malaria include atovaquone, doxycycline, and artemisinin-based combination therapies (ACTs). ACTs are currently the most effective drugs for treating malaria.

By Distribution Channel:

• Hospital Pharmacy: Hospital pharmacies are a major distribution channel for antimalarial drugs, as hospitals are often the first point of care for patients with severe malaria. These pharmacies stock a wide range of anti-malarial drugs and can provide them to patients as needed.
• Retail Pharmacy: Retail pharmacies, such as independent drug stores and chain pharmacies, are another important distribution channel for antimalarial drugs. These pharmacies typically stock a smaller range of drugs than hospital pharmacies but are more convenient for patients who do not require hospitalization.
• E-Commerce and Other Distribution Channels: E-commerce and other non-traditional distribution channels, such as mail-order pharmacies and online pharmacies, are also becoming increasingly important in the Antimalarial Drugs Market. These channels offer convenience and accessibility to patients, particularly in rural areas where access to traditional pharmacies may be limited.

Antimalarial Drugs Market – Regional Analysis

The Antimalarial Drugs Market can be analyzed by region, which includes:

• North America: The North American region is a major market for antimalarial drugs, primarily due to the presence of major pharmaceutical companies and high healthcare expenditure. However, the prevalence of malaria in this region is low, so the market is mainly driven by exports to malaria-endemic regions.
• Europe: Europe is another major market for antimalarial drugs, primarily due to a large number of travellers from Europe to malaria-endemic regions. The market is also driven by the presence of major pharmaceutical companies in the region.
• Asia Pacific: The Asia Pacific region is the largest and fastest-growing market for antimalarial drugs, primarily due to the high prevalence of malaria in the region. Countries such as India and China have a large population at risk of malaria, which has led to high demand for anti-malarial drugs.
• Latin America: The Latin America region is a growing market for antimalarial drugs, driven by the high prevalence of malaria in countries such as Brazil and Peru.
• Middle East and Africa: The Middle East and Africa region is also a major market for antimalarial drugs, primarily due to the high prevalence of malaria in the region. Countries such as Nigeria and the Democratic Republic of Congo have a high burden of malaria, which has led to high demand for antimalarial drugs.

Overall, the regional analysis of the Antimalarial Drugs Market reflects the varying prevalence of malaria in different regions and the corresponding demand for anti-malarial drugs. The market is expected to grow fastest in the Asia Pacific region due to the large population at risk of malaria in the region.

Competitive Landscape – Antimalarial Drugs Market

The Antimalarial Drugs Market is highly competitive with the presence of several established players as well as new entrants. Some of the key players operating in the market include

• Novartis International AG: This Swiss multinational pharmaceutical company is one of the world’s leading manufacturers of antimalarial drugs. The company’s flagship product in this space is Coartem, which is a combination therapy of artemether and lumefantrine.
• GlaxoSmithKline plc: This British pharmaceutical company is another major player in the antimalarial drugs market. Its key product in this space is Malarone, which is a combination of atovaquone and proguanil.
• Sanofi: This French multinational pharmaceutical company has a range of antimalarial drugs in its portfolio, including Coartem, Artesunate Winthrop, and Eurartesim.
• Pfizer Inc.: This American pharmaceutical company has a strong presence in the antimalarial drugs market with its product, Chloroquine, which has been in use for many years as a treatment for malaria.
• Cipla Limited: This Indian pharmaceutical company is a major supplier of generic antimalarial drugs, including artemether-lumefantrine and quinine sulfate.
• Mylan NV: This American pharmaceutical company is another major supplier of generic antimalarial drugs, including artemether-lumefantrine and quinine sulfate.
• Ipca Laboratories Limited: This Indian pharmaceutical company is a leading supplier of antimalarial drugs, including artemether-lumefantrine and atovaquone-proguanil.

These companies are focusing on strategies such as mergers and acquisitions, collaborations, and partnerships to strengthen their market position. They are also investing heavily in research and development to develop innovative antimalarial drugs and improve the efficacy of existing drugs. Additionally, they are expanding their distribution networks and increasing their presence in emerging markets to capitalize on the growing demand for antimalarial drugs. Overall, the competitive landscape of the Antimalarial Drugs Market is characterized by intense competition, rapid technological advancements, and the need for continuous innovation to stay ahead in the market. The key players are expected to continue investing in research and development and strategic partnerships to expand their market share and increase profitability.

The Antimalarial Drugs Market is segmented as follows:

By Drug Class

• Quinine
• Chloroquine
• Proguanil
• Mefloquine
• Pyrimethamine
• Others

By Malaria Type

• Plasmodium Falciparum
• Plasmodium Vivax
• Plasmodium Malariae
• Plasmodium Ovale

By Mechanism of Action

• Treatment for Malaria
• Prevention from Malaria

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• E-Commerce & Other Distribution Channel

By Region

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America